Dual incretin (GIP/GLP-1) injection approved for diabetes, with strong weight-loss outcomes
"So if something feels off, say something." Novo Nordisk, manufacturer of Ozempic and Wegovy, provided the below statement to Fox News Digital related to the study
In the UK, canagliflozin is licensed not only for glycaemic control but also, at a dose of 100 mg once daily, for reducing the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and for the treatment of adults with type 2 diabetes and diabetic kidney disease (albuminuria)
All protocols described here are based on animal studies or limited clinical data and are presented for educational purposes
The rheology properties further confirmed that the hydrogel was successfully prepared
The protocol begins at 2.5mg per week for four weeks, then escalates based on tolerability and response